Leukemia professor & chair
@MDAndersonNews
. Unable to provide medical advice here; contact the clinic, or call 877-632-6789 for an appointment. Views are mine.
Chemo-free combination of ponatinib + blinatumomab is potentially curative in Ph+ ALL w/o need for intensive chemo or allo-SCT. This is new standard of care in Ph+ ALL.
Jabbour, Short, Kantarjian of
@MDAndersonNews
#Leukemia
via
@TheLancetHaem
#leusm
A combination of 2 targeted drugs, ponatinib+ blinatumomab, WITHOUT ANY CHEMOTHERAPY, results in 100% complete response rate, 85% complete molecular remission rate in newly diagnosed pts w/ Ph-positive
#ALL
.
@MDAndersonNews
study led by
@NicholasShortMD
& Jabbour
#leusm
#ASCO21
A study led by our Dr. Elias Jabbour shows a chemo-free combination results in 100% complete response rate in newly diagnosed patients with Ph+ acute lymphoblastic leukemia.
Dr. Nicholas Short presents the findings at
#ASCO21
:
@NicholasShortMD
#EndCancer
Out now in
@TheLancetHaem
via
@MDAndersonNews
Leukemia | Outcomes of venetoclax combined with IC in
#AML
| VEN+IC👉 improved MRD-negative CR rates, transition to alloHSCT, and EFS compared to IC alone.
#leusm
A fixed blast % to discriminate
#MDS
from
#AML
is overly simplistic. Patient characteristics and genomics are key factors to identify optimal therapy.
Time to Blur the Blast Boundaries
Courtney DiNardo MD,
@garciamanero
,
@DrHKantarjian
@MDAndersonNews
Gamma delta T cells are a novel immunotherapy for AML. Recent review from our group We have clinical trials w Aza Ven & gd2T cell activating ICT01 for Newly Dx AML, & allogeneic gd1T cells for R/R
#AML
#leusm
How We Incorporate Venetoclax in Treatment Regimens for
#AML
- Maximizing Efficacy and Minimizing Toxicities
Abhishek Maiti, MBBS, Marina Konopleva, MD, PhD |
@MDAndersonNews
via
@PPO_journal_lww
#leusm
Published now in
@JCO_ASCO
from
@MDAndersonNews
Leukemia | CLAD/LDAC/VEN alternating with AZA/VEN in older
#AML
➡️ CR/CRi 93%, MRD neg 84%!! 2-yr CR duration 76% and 2-yr OS 64%!
Potentially practice changing regimen.
#leusm
Multinational randomized trial of ibrutinib + venetoclax in
#CLL
confirms the initial pilot trial results from
@MDAndersonnews
of high rate of disease elimination with a oral targeted therapy of finite treatment duration |
W. Wierda
@wwierda
via
@JCO_ASCO
The simultaneous combination of ponatinib and blinatumomab highly effective: MRD-negativity rate of 83% by RT-PCR and 98% by NGS with 3-year OS rate of 91.
@MDAndersonNews
#Leukemia
@JCO_ASCO
#leusm
Low-dose azacitidine plus venetoclax maintains remissions with manageable side effects in patients with
#AML
unable to complete standard consolidation strategies (2-year modified RFS and OS of 56% and 72%).
@MDAndersonNews
#Leukemia
@TheLancetHaem
#leusm
Ponatinib and mini-hyperCVD w/ sequential blinatumomab is an effective combination for newly-diagnosed and R/R Philadelphia-positive
#ALL
and
#CML
in lymphoid blast phase.
Read more about our phase 2 trial 👇
@AjHematology
@MDAndersonNews
#Leukemia
#leusm
FDA confirms CR and EFS correlate with OS in
#AML
and of value as surrogate trial endpoints = should translate into faster AML trial timelines to bring effective therapies to AML | Courtney DiNardo, MD &
@DanPollyea
| via
@JCO_ASCO
#leusm
@MDAndersonNews
Combo of venetoclax+ hypomethylating agent = high rates of durable remission and overall survival in both newly diagnosed and R/R IDH1/2-mutated
#AML
@Nature
@MDAndersonNews
#leusm
Congratulations to Courtney D. DiNardo, M.D., on her publication of 'Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid
#Leukemia
'. |
#leusm
#AML
Nice review by
@NicholasShortMD
and colleagues on the prognostic and therapeutic impact of MRD in
#AML
. Enrollment of patients with MRD+ AML on clinical trials is imperative to improve outcomes.
#leusm
#leukemia
Very exciting new treatment options in
#AML
Harnessing the Therapeutic Value of Venetoclax: A Breakthrough Therapy in Acute Myeloid
#Leukemia
| Andrew H. Wei, MBBS, PhD; Gail J. Roboz , MD; and Hagop M. Kantarjian, MD | via
@ASCO_pubs
#leusm
Non-Chemo regimen of venetoclax + gilteritinib highly active in R/R FLT3+ AML (including exposed to prior FLT3 inhibitors). Published now
@JCO_ASCO
#leusm
#AML
Check the largest single-institution experience reported on treatment-free remission (TFR) in
#CML
--> Deep molecular remission for 5 + years associated with the highest chance (80+%) of successful TFR.
@MDAndersonNews
@FadyyHaddad
@AjHematology
#leusm
Remembering Dr. Freireich, of
@MDAndersonNews
, a giant in cancer research.
Remembering Emil J. Freireich: A Portrait of Courage and Innovation in Cancer Research—March 16, 1927 to February 1, 2021 via
@ASCO_pubs
#leukemia
#leusm
Dose-dense mini-hyper-CVD, INO and blina achieves NGS MRD negativity in >90% of pts with new dx B-ALL. A clinical trial at
@MDAndersonNews
is ongoing.
@NicholasShortMD
Clinical Lymphoma, Myeloma and Leukemia
So gratifying to see this great man honored by
@ASCO
with highest honors. Dr. Freireich was a great physician, scientist, mentor and friend and personally mentored hundreds of our current thought leaders throughout oncology and hematology.
@MDAndersonNews
#leusm
#leukemia
HCVAD chemotherapy ➡Still plays an important role in Tx of
#BPDCN
, even in era of
#CD123
-targeted therapy; high response rates, incorporation of CNS-directed Tx, offering possibilities for combination/total Tx approaches in
#BPDCN
|
@doctorpemm
Chemo-free regimens (TKIs-blinatumomab) highly effective in Ph+ALL; may replace intensive chemoRx and allo SCT in most such patients in the future.
Clinical Lymphoma, Myeloma and Leukemia
@NitinJainMD
@NicholasShortMD
@MDAndersonNews
#leusm
Our new paper by
@NicholasShortMD
in
@AjHematology
reviews the decades of clinical research and dose optimization of HMAs in
#MDS
and
#AML
. Novel combinations and oral formulations are now expanding the role of HMAs in myeloid diseases.
#leusm
Join us in welcoming Alexandre Bazinet, MDCM, MSc to our
@MDAndersonNews
#Leukemia
Faculty!
Dr. Bazinet first joined MD Anderson in 2021 as a fellow. We are pleased to have him on our team.
#leusm
#EndCancer
Frontline use of blinatumomab and/or INO with chemoRx + close monitoring of NGS-ClonoSEQ MRD allows us to avoid alloSCT in most pts with B-cell ALL. CAR T-cells can be considered for high-risk pts or those w/ persistent MRD.
@NicholasShortMD
Our
@AUB_Lebanon
2019 graduation was the occasion we awarded two time alumnus and former Internal Medicine Chief resident
@DrHKantarjian
an honorary doctorate. Hagop is a hero for leukemia patients and a role model for oncologists and hematologists everywhere.
📢Out now in
@AjHematology
via
@MDAndersonNews
#Leukemia
👉 Extended follow up (median 20 mo.) with expanded enrollment (N=45) of FLAG-IDA-VEN in ND-AML | ORR: 98% | CRc: 89% | ⏫ MRD-neg CRc: 93%| 24-month OS 85% in ELN adv. risk w/o TP53 mut.
Link👇
Join our
@MDAndersonNews
Emil J Freireich Hematology Grand Rounds as I present “What is new at ASH and Leukemia 2022” | Dec. 15, 2021 8 am CST | |
#leusm
#MedEd
#ASH21
Key Paper in treatment of Older AML ➡️out in
@AjHematology
Incorporation of venetoclax-based therapy & increased utilization of Allo SCT has led to higher rates of quality remissions & significant improvement in OS for patients aged > 60 years.
@Tapkadia
In this Ph1b trial, single agent SQ blinatumomab resulted in a high MRD-negative complete remission rate & an acceptable safety profile in heavily pretreated adults w/ R/R B-ALL
Elias Jabbour of
@MDAndersonNews
#Leukemia
@AjHematology
#leusm
Prolonged exposure to blina is associated w/ favorable outcomes in pts w/ MRD positive B-ALL at a threshold of 10-4 or more & may spare the need for allogeneic SCT w/ 73% of pts achieving MRD negative remission and 3-year RFS and OS rates of 63% and 67%.
Join the
@UTHealthHouston
Hematology and Oncology Grand Rounds as I present "Therapy and Research in Acute Lymphoblastic
#Leukemia
in 2021" | Monday, August 30, 8 am CST | Zoom Attendance Only
#leusm
#MedEd
#ALL
Led by our own Dr. Verstovsek of
@MDAndersonNews
#Leukemia
, important Ph3 study MOMENTUM: Momelotinib vs danazol resulted in clinically significant improvements in MF-associated anemia+sxs+spleen response+favorable safety.
@TheLancet
#MPNSM
Thrombosomes, if validated to be as beneficial or superior to platelet transfusions in thrombocytopenia/bleeding, can be the best solution to platelet shortages, & replace them in thrombocytopenia/bleeding
Maro Ohanian, DO
@MDAndersonNews
via
@AjHematology
Now out in
@Ajhematology
reporting Ph II trial of CLIA +/-Sorafenib in newly diagnosed
#AML
. With a median F/U of 76 months, CR/CRi Overall was 83% (74% MRD neg) & 4-yr OS of 57%; Among FLT3-ITD, CR/CRi was 95% (81% MRD neg), w/ 5-yr OS of 59%.
@TapKadia
Join our virtual
@MDAndersonNews
Emil J Freireich Hematology Grand Rounds as I present “CML in 2022- Current Status and Research Directions” | April 6, 2022 8 am CST | |
#leusm
#MedEd
#CML
Please join our
@MDAndersonNews
Emil J Freireich Hematology Grand Rounds: “Chimeric Antigen Receptor T-cell Therapy for Hematologic Malignancies” presented by Jim Kochenderfer, M.D., of
@NCIResearchCtr
| May 5, 8 am CST | |
#leusm
#MedEd
#CART